stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. ARDX
    stockgist
    HomeTop MoversCompaniesConcepts
    ARDX logo

    Ardelyx, Inc.

    ARDX
    NASDAQ
    Healthcare
    Biotechnology
    Waltham, MA, US395 employeesardelyx.com
    $5.92
    -0.18(-3.03%)

    Mkt Cap $1.5B

    $3.28
    $7.99

    52-Week Range

    At a Glance

    AI-generated

    Ardelyx, Inc.

    Revenue breakdown: Non Cash Royalty Related To Sale Of Future Royalties (34.2%), Product IBSRELA (33.1%), Product XPHOZAH (17.2%).

    8-K
    Ardelyx, Inc. filed an 8-K on 2026-02-19 disclosing results of operations via Exhibit 99.1 press release and earnings presentation in Exhibit 99.2. Items 2.02, 7.01, and 9.01 are referenced, with exhibits not deemed filed under the Exchange Act.

    $1.5B

    Market Cap

    $410M

    Revenue

    -$62M

    Net Income

    Employees395
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Non Cash Royalty Related To Sale Of Future Royalties34.2%($529M)
    Product IBSRELA33.1%($513M)
    Product XPHOZAH17.2%($267M)
    License5.6%($87M)
    Product And Service Other5.5%($86M)
    Product Supply Revenue4.3%($67M)

    Revenue by Geography

    US90.2%($780M)
    Asia Pacific9.8%($85M)
    North America0.1%($479.0K)
    Activity

    What Changed Recently

    Financial Results
    Feb 18, 2026

    , including Exhibit 99.1 hereto, shall not be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be inc

    Financial Results
    Jan 7, 2026

    Results of Operations and Financial Condition. On January 8, 2026, Ardelyx, Inc. (the “Company”) announced: • Unaudited U.S. net product sales revenue of IBSREL

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    SYRESpyre Therapeutics, Inc.$47.67-2.52%$2.9B-95.3
    STOKStoke Therapeutics, Inc.$32.73+2.31%$1.9B-283.3
    ZYMEZymeworks Inc.$25.77-0.66%$1.9B-22.3
    BCRXBioCryst Pharmaceuticals,...$9.03-3.78%$1.9B7.8
    PHVSPharvaris N.V.$28.50-3.21%$1.9B-8.3
    NTLAIntellia Therapeutics, In...$13.13-1.09%$1.6B-3.4
    TRVITrevi Therapeutics, Inc.$11.93+3.02%$1.5B-36.6
    MAZEMaze Therapeutics, Inc.$28.82-0.77%$1.4B-17.8
    Analyst View
    Company Profile
    CIK0001437402
    ISINUS0396971071
    CUSIP039697107
    Phone510 745 1700
    Address400 Fifth Avenue, Waltham, MA, 02451, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice